Упрощенная HTML-версия
126
167.
Stroes E.S. Vascular function in the forearm of hypercholesterolae-
mic patients off and on lipid-lowering medication / E.S. Stroes, Н.А. Koomans,
T.J. Rabelink et al. // Lancet. – 1995. – V. 346. – P. 467-471.
168.
Suri C. Require role of angiopoetin-1, a ligand for TIE-2 receptor,
during embryonic angiogenesis / C. Suri, P.F. Jones, S. Patan et al. // Cell. –
1996. – V. 87. – P. 1171-1180.
169.
Taddei S. Vasodilatation to acetylcholin in primary and secondary
forms of hypertention / S. Taddei, A. Virdis, P. Mattei et al. // Hypertension. –
1993. – V.21. – P.929-933.
170.
Taddei S. Defective L.argining-nitric oxide pathway in offspring of
essential hypertensive patients / S. Taddei, A. Virdis, P. Mattei et al. // Circula-
tion. – 1996. – V.94. – P.1298-1303.
171.
Taddei S. Different effect of a calcium-antagonist and a beta-blocker
on nitric oxide availability in essential hypertensive patients / S. Taddei, A.
Virdis, L. Ghiadoni et al. // J. Hypertens. –1999. – V. 17. – P. 129-132.
172.
Taddei S. Endothelial dysfunction in hypertension / S. Taddei, A.
Virdis, L. Ghiadoni et al. // J. of Nephrology. – 2000. – V. 13. – P. 205-210.
173.
Tawakol A. Hyperhomocysteinemia is associated with impaired en-
dotheliurn - dependent vasodilation function in humans / A. Tawakol, T. Ornland,
M. Gerhard et al. // Circulation. – 1997. – V. 95. – P. 1119-1121.
174.
The MRIFT Research Group. Multiple Risk Factor Intervention Tri-
al. Risk Factor changes and mirtality results. // J Am Med Assoc.– 1982.– V.
248.– P. 1465–1477.
175.
Tiengo A. Pathogenesis and therapy of plurimetabolic syndrome / A.
Tiengo, P. Avogaro, S. Del Prato // Nutr. Metab. Cardiovasc. Dis. – 1996. – V. 6.
– P. 187-192.
176.
Ting H.H. Vitamin С improves enoothelium-dependent vasodilatiiin
in patients with non-insulin-dependent diabetes mellitus / H.H. Ting, F.K. Timini,
K.S. Boles el al. // J. Clin. Investig. – 1996. – V. 97. – P. 22-28.